Change from originator infliximab to biosimilar does not affect 1‐year outcome in children with inflammatory bowel disease

Documenti analoghi

• Systemic lupus erythematosus: An imitator for inflammatory bowel disease
  di: Elizabeth A. Reznikov, et al.
  Pubblicazione: (2024)
• Eosinophilic mesenteric vasculitis presenting as inflammatory bowel disease
  di: Razan Alkhouri, et al.
  Pubblicazione: (2025)
• Myointimal hyperplasia of the mesenteric veins mimicking inflammatory bowel disease in a 13‐year‐old patient
  di: Dua Abuquteish, et al.
  Pubblicazione: (2024)
• Frequency and impact of repeat colonoscopy as a treat‐to‐target approach in pediatric inflammatory bowel disease
  di: Kari Noel VanEvery, et al.
  Pubblicazione: (2025)
• The Transition Care Index: Standardizing comprehensive transition and transfer for young adults with inflammatory bowel disease
  di: Hilary K. Michel, et al.
  Pubblicazione: (2025)